No Data Yet
Novo Nordisk is seeking regulatory approval for a new 7.2 mg higher-dose version of its weight-loss drug Wegovy to compete more effectively against Eli Lilly's Zepbound.
The iShares U.S. Healthcare ETF (IYH) has posted a year-to-date return of 12.07%, heavily influenced by its 14.12% allocation to Eli Lilly.
Eli Lilly's oral GLP-1 drug, orforglipron, helped patients maintain all but 0.9 kg of weight loss previously achieved with injectable Wegovy, according to 52-week Phase 3 trial data.
On December 18, 2025, Eli Lilly and Company announced it will reduce the prices of its diabetes and weight-loss drug Mounjaro in Canada by 20% or more.
Pfizer signed a $2.1 billion licensing deal with China's YaoPharma to develop a GLP-1 weight loss pill, marking a significant investment to capture a share of the growing obesity treatment market.
China's new commercial drug insurance program will cut the price of Alzheimer's drug Leqembi by up to 50% from its current US$28,400 annual cost, impacting pharmaceutical firms like Eisai and Eli Lilly.
Three major healthcare firms, Eli Lilly, Amgen, and Stryker, announced dividend increases in December 2025, with Eli Lilly leading with a 15.3% hike to its quarterly payout.
South Korean biopharma MEDI&GENE entered a development agreement with Eli Lilly on December 17 to advance its next-generation obesity therapeutic toward clinical trials.
On December 17, 2025, private oncology firm NanOlogy appointed 35-year pharma veteran David J. Arthur as CEO to accelerate its clinical development pipeline.
The global drug delivery devices market is projected to reach US$450.7 billion by 2035, spurred by surging revenues from biologic drugs that are fueling multi-billion dollar investments in manufacturing capacity from pharmaceutical leaders.
The ulcerative colitis treatment market is projected for significant growth through 2034, driven by a rising prevalence of 1.5 million diagnosed U.S. cases in 2024 and a strong pipeline of novel therapies.
Market expert Coons identified Big Pharma stocks as 'way undervalued' on December 17, highlighting Eli Lilly and Merck as key opportunities despite a 1.19% dip in LLY shares.
Eli Lilly's projected 42% sales growth, driven by its GLP-1 drugs, positions it as a stronger investment than Merck, which faces a 2028 patent cliff for its key drug, Keytruda.
On December 16, 2025, Form Health announced a new partnership with Eli Lilly and Novo Nordisk to offer employers predictable pricing for GLP-1 obesity medications, as only 19% of companies currently cover them due to cost concerns.
Eli Lilly and Company announced CEO David A. Ricks will speak at the J.P. Morgan Healthcare Conference on January 13, 2025, an event closely watched by investors.
Piper Sandler lowered its price target for Constellation Brands (STZ) to $135 from $155, citing risks from the increasing use of GLP-1 weight-loss drugs. This action highlights growing investor concern over the secondary economic impacts of these pharmaceuticals on consumer discretionary sectors.
Gilead's Kite unit reported positive new analysis for its Yescarta cell therapy as a second-line lymphoma treatment, reinforcing its oncology franchise. The win provides a crucial boost as the company navigates a major setback in its lung cancer pipeline, highlighting the high-stakes nature of its diversification strategy.
Abbott Laboratories showcases a strong balance sheet with reduced debt and high interest coverage, presenting a stable profile amid a volatile healthcare sector focused on obesity drugs and policy shifts.
Merck announced an increased dividend to $0.85 per share, creating a 3.4% forward yield. The move signals confidence in its financial stability and commitment to shareholder returns, even as the company faces a new FDA safety review for its RSV antibody treatment, Enflonsia.
HSBC upgraded AbbVie to a "Buy" rating following a strong quarterly report that included higher earnings guidance and a dividend increase, signaling confidence in the company's financial health and market position.